Empowering precision: Revvity Omics in clinical and pharma solutions
Reliable and early diagnosis is the cornerstone of disease management. With cutting-edge technologies and a commitment to innovation, we provide comprehensive solutions to support clinicians and biopharma organizations dedicated to unraveling the mysteries of common and rare diseases.
Who we are
Why choose Revvity Omics
Acceleration
With over 30 years of expertise, our team, led by renowned geneticists, are pioneering newborn screening and genomic services by employing state-of-the-art NGS technologies.
Confidence
We prioritize rapid results delivery, boasting industry-leading Turn-Around-Times (TATs) for panels, exomes, and genomes. Our comprehensive and flexible testing menu helps you to find the right test tailored to the patient's needs, supported by multiple sample types for swift and timely collection.
Accessibility
We are dedicated to passing on cost savings achieved through efficient automation to our clients. Our industry-leading pricing structures, covering various testing platforms from genome to targeted single-site testing, provide cost certainty with transparent pricing based on the specific testing platform, whether it's a panel, exome, or genome.
Explore our solutions
Omics resources
We have an expansive library of testing resources that includes patient guides, specimen collection requirements, sample collection videos, publications and lab accreditations.
Who we serve
Healthcare providers
At Revvity Omics, patients and healthcare providers are at the heart of what we do. We believe that genomic testing is a deep-rooted partnership and are committed to making it accessible and meaningful to the patients and families we serve around the world.
Patients & parents
Revvity Omics pairs decades of newborn screening experience with leading-edge clinical genomic testing to offer one of the world’s most comprehensive programs for detecting clinically significant genomic changes. Working together with physicians, we aim to deliver knowledge that can empower health.
Pharma & research
Revvity Omics has a long history of screening and identifying patients with rare diseases. Since our founding in 1994, we have performed over 300 million genOMIC tests. Partner with us to harness the latest in genomic testing.
This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.
How can we help you?
We are here to answer your questions.